Vitro Diagnostics, Inc. (OTCBB: VODG) dba Vitro Biopharma has received funding related to exercise of outstanding Class A warrants held by a group of three private investors. These funds will be used primarily to advance the Company’s stem cell technology for the production of human beta islets from stem cell lines that the Company has previously developed. An immediate goal is the commercialization of stem cell-derived human beta islets for applications in research, drug development and drug discovery. In addition, the terms of the agreement underlying this funding include expansion of the Board of Directors and efforts to increase shareholder equity through the reduction of corporate liabilities.

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG) http://www.vitrodiag.com has generated over 30 adult stem cell lines from human pancreatic tissues. Vitro owns patent-pending technology for the generation and differentiation of adult stem cell lines and has applied this technology to production of beta islets from stem cell lines generated by the Company. These cell lines may have application in drug development and discovery, diabetes research and therapy. The Company manufactures the VITROCELL™ brand of human pancreatic-derived cell lines and related products for research and commercial applications.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Vitro Diagnostics, Inc.
Dr. James Musick, 720-859-4120
Chief Executive Officer
jim@vitrodiag.com